Document is current
Any future updates will be listed below
-
Authors
Alsaqaaby, Moath S.
le Roux, Carel W. https://orcid.org/0000-0001-5521-5445
-
Funding
Funding for this research was provided by:
Health Research Board
Johnson and Johnson
Novo Nordisk
Science Foundation Ireland
Irish Research Council
GI Dynamics
Eli Lilly
Boehringer-Ingelheim
AnaBio
Herbalife
Glia
Irish Society of Clinical Nutrition and Metabolism
Keyron
- License Information
-
More Information
Article History
Received: 27 December 2022
Accepted: 7 March 2023
First Online: 4 April 2023
Declarations
:
: ClR reports grants from the Irish Research Council, Science Foundation Ireland, Anabio, and the Health Research Board. He serves on advisory boards of Novo Nordisk, Herbalife, GI Dynamics, Eli Lilly, Johnson & Johnson, Sanofi Aventis, AstraZeneca, Janssen, Bristol-Myers Squibb, Glia, and Boehringer Ingelheim. ClR is a member of the Irish Society for Nutrition and Metabolism outside the area of work commented on here. He is the chief medical officer and director of the Medical Device Division of Keyron since January 2011. Both of these are unremunerated positions. ClR was a previous investor in Keyron, which develops endoscopically implantable medical devices intended to mimic the surgical procedures of sleeve gastrectomy and gastric bypass. He continues to provide scientific advice to Keyron for no remuneration. The other authors declare no conflict of interest.
: This article does not contain any studies with human or animal subjects performed by any of the authors.
